Trial reportAmerican journal of respiratory and critical care medicine2008
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
Trial report in American journal of respiratory and critical care medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00883129 (Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease), which is not on this map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2018Pooled it
- Cyclophosphamide for connective tissue disease-associated interstitial lung disease.The Cochrane database of systematic reviews · 2018Pooled it
- [Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS)].Zeitschrift fur Rheumatologie · 2008Guideline
- Trial
- Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.Arthritis and rheumatism · 2011Trial
- Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.Arthritis and rheumatism · 2011Trial
- Trial
- Biological correlates of radiological features of systemic sclerosis interstitial lung disease.ERJ open research · 2025Article
- Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease.Journal of thoracic disease · 2021Article
- Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?Therapeutic advances in musculoskeletal disease · 2021Review
- Review
- Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2020Article
- Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.Open access rheumatology : research and reviews · 2019Article
- Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2019Article
- Determinants of mortality in systemic sclerosis: a focused review.Rheumatology international · 2018Review
- Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.Clinical rheumatology · 2018Observational
- Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.Annals of the American Thoracic Society · 2016Review
- Neutrophilic Alveolitis and High Serum Pro-Brain Natriuretic Peptide Level may be Indicators of Pulmonary Functional Impairment in Connective Tissue Disorders.Archives of rheumatology · 2016Article
- Management of Systemic-Sclerosis-Associated Interstitial Lung Disease.Rheumatic diseases clinics of North America · 2015Review
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe presence of inflammatory cells on bronchoalveolar lavage is often used to predict disease activity and the need for therapy in systemic sclerosis-associated interstitial lung disease.
objectivesTo evaluate whether lavage cellularity identifies distinct subsets of disease and/or predicts cyclophosphamide responsiveness.
methodsPatients underwent baseline lavage and/or high-resolution computed tomography as part of a randomized placebo-controlled trial of cyclophosphamide versus placebo (Scleroderma Lung Study) to determine the effect of therapy on forced vital capacity. Patients with 3% or greater polymorphonuclear and/or 2% or greater eosinophilic leukocytes on lavage and/or ground-glass opacification on computed tomography were eligible for enrollment. MEASUREMENTS AND MAIN
resultsLavage was performed in 201 individuals, including 141 of the 158 randomized patients. Abnormal cellularity was present in 101 of these cases (71.6%) and defined a population with a higher percentage of men (P = 0.04), more severe lung function, including a worse forced vital capacity (P = 0.003), worse total lung capacity (P = 0.005) and diffusing capacity of the lung for carbon monoxide (P = 0.004), more extensive ground-glass opacity (P = 0.005), and more extensive fibrosis in the right middle lobe (P = 0.005). Despite these relationships, the presence or absence of an abnormal cell differential was not an independent predictor of disease progression or response to cyclophosphamide at 1 year (P = not significant).
conclusionsThe presence of an abnormal lavage in the Scleroderma Lung Study defined patients with more advanced interstitial lung disease but added no additional value to physiologic and computed tomography findings as a predictor of progression or treatment response. Clinical trial registered with www.clinicaltrials.gov (NCT 000004563).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.